Click chemistry

Shasqi to Present Data on Novel Tumor-Targeted Drug Activation Technology at 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 5, 2024
HER2, Toxicity, Therapeutic index, SAN, MMAE, Spacecraft, Abstract (summary), Nobel Prize, AACR, Neoplasm, Safety, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.

Key Points: 
  • SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.
  • The posters will describe data generated with Shasqi's CAPAC® (Click Activated Protodrugs Against Cancer) approach.
  • Shasqi is advancing a pipeline of assets based on validated targets and payloads.
  • The posters presented at the AACR meeting will show preclinical efficacy and safety data for assets targeting HER2, TROP2, and NECTIN-4, each paired with either an MMAE or exatecan payload.

Shasqi Appoints Travis Biechele, Ph.D. as VP of Research to Lead Pipeline Development

Retrieved on: 
Monday, March 11, 2024
Pharmacology, Therapeutic index, Seagen, SAN, Patient, University, Spacecraft, MD, Neoplasm, CAPAC, ADC, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.
  • Biechele has over two decades of experience in oncology research, with a focus on developing antibody-drug conjugates (ADCs), with both Seagen (now Pfizer) and Merck.
  • Shasqi's pipeline is composed of a range of tumor-targeted activators against validated antigen targets that are combined with protodrugs based on a range of validated payloads.
  • Prior to Merck, Biechele spent 10 years at Seagen (now Pfizer), where he played a pivotal role in the development of ADC technology.

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024
Research, General Health, Radiology, Pharmaceutical, Biometrics, Medical Devices, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Organic chemistry, FNIH, Neuroscience, Doctor of Philosophy, Nobel Prize in Chemistry, NIH, Professor, SVP, Johnson & Johnson, Hartmuth C. Kolb, Neurodegenerative disease, Imperial College London, Biomedicine, Biomarker, Siemens Healthineers, Enigma, EB, Scripps Research, CNS, Associate, Disease, CSO, Diagnosis, PET, Click chemistry, Central nervous system disease, Nobel Prize, Management

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.

Shasqi Expands Board of Directors with Appointment of Biopharma Executives

Retrieved on: 
Thursday, January 4, 2024
Neoplasm, 600 (number), Amgen, Virus, Shasqi, Spacecraft, CMO, SAN, Doctor of Philosophy, Click chemistry, Cancer, Noel McCamish, Genentech, Therapy, NCI

Dr. Klein is an Independent Director on several biotech boards, as well as a venture partner for Ysios Capital.

Key Points: 
  • Dr. Klein is an Independent Director on several biotech boards, as well as a venture partner for Ysios Capital.
  • She has previously held positions at Genentech, and the NCI as co-founder and Research Director of NCI-Navy Breast Center.
  • Drs Klein and McCamish join existing board members Juan Jaen, PhD and José M. Mejía Oneto, M.D., Ph.D., Shasqi CEO and founder.
  • "I am delighted to welcome these esteemed executives to Shasqi's board" said Dr. Mejía Oneto.

Shasqi to Expand Existing Research Collaboration to Advance Targeted Cancer Treatment

Retrieved on: 
Wednesday, October 4, 2023
Human, Toxicity, Research, Doctor of Philosophy, Nobel Prize in Chemistry, Chemistry, Click chemistry, Cancer, MD, SAN, CAPAC, Biology, Neoplasm, Pharmaceutical industry, Shasqi

Through the collaboration, Shasqi will apply its clinically validated Click Activated Protodrugs Against Cancer (CAPAC®) technology to the development of new cancer therapies.

Key Points: 
  • Through the collaboration, Shasqi will apply its clinically validated Click Activated Protodrugs Against Cancer (CAPAC®) technology to the development of new cancer therapies.
  • The collaboration will expand research on Shasqi's intratumorally injected biopolymer (SQL70), allowing for an additional payload to be developed and advanced through preclinical testing.
  • Using CAPAC, Shasqi is targeting high doses of cancer drugs directly to the site of the tumor, while minimizing toxicity to healthy cells.
  • "Expansion of this collaboration is a testament to the collaborative, productive relationship we have built together."

Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor

Retrieved on: 
Monday, September 18, 2023
ACC, Nobel Prize, National academy, Stanford University, Nobel Prize in Chemistry, Cancer, Coronavirus Scientific Advisory Board, Howard Hughes Medical Institute, Cell, Click chemistry, Hematological Cancer Research Investment and Education Act, Patient, Nobel, Anne, Report of the 1st Annual Symposium on Relaxed Improvisation, Pharmaceutical industry, Medical device, Chemistry, Invention

ALAMEDA, Calif. and TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced that Nobel Laureate Carolyn Bertozzi, Ph.D., was recently appointed Chief Scientific Advisor.

Key Points: 
  • ALAMEDA, Calif. and TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced that Nobel Laureate Carolyn Bertozzi, Ph.D., was recently appointed Chief Scientific Advisor.
  • Dr. Bertozzi's appointment was celebrated at Acepodia's Annual Symposium in San Francisco Bay Area, CA on September 13.
  • Dr. Bertozzi was awarded the 2022 Nobel Prize in Chemistry for discovering a novel form of click chemistry, known as bioorthogonal chemistry.
  • As Chief Scientific Advisor, Dr. Bertozzi will lead Acepodia's Scientific Advisory Board in guiding the company's scientific progress and offering insights based on their relevant experience.

Thompson Street Capital Partner’s Vector Laboratories Acquires Quanta BioDesign

Retrieved on: 
Tuesday, July 25, 2023
Professional Services, Health, Apps, Applications, Technology, Finance, Pharmaceutical, Biotechnology, Quanta, Vector, Doctor of Philosophy, Click chemistry, Plain City, Caliper Life Sciences, Acquisition, TSCP, Drug discovery, Immunohistochemistry, Growth, Fine chemical

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Quanta BioDesign , the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications, by Vector Laboratories , a portfolio company of TSCP and the pioneer of innovative proteomic and glycomic research solutions.

Key Points: 
  • Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Quanta BioDesign , the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications, by Vector Laboratories , a portfolio company of TSCP and the pioneer of innovative proteomic and glycomic research solutions.
  • This acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.
  • “This acquisition supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa V. Sellers, PhD, CEO of Vector Laboratories.
  • Vector was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence.

EQS-News: Defence Therapeutics Inc.: DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO

Retrieved on: 
Tuesday, July 18, 2023
DOTA, Trastuzumab, Radiopharmaceutical, Radiochemistry, Azide, Immunotherapy, USD, SAS, Click chemistry, Insight Partners, Orano, Collaboration, Therapy, Pharmaceutical industry, Fine chemical

Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA (“Orano”), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence’s intracellular targeting technology.

Key Points: 
  • Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA (“Orano”), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence’s intracellular targeting technology.
  • The first milestone consists of synthesising the AccuTOXTM peptide containing the DOTA chelator and the Azide moiety.
  • The DOTA chelator will be used to encapsulate the radioactive molecule, while the Azide moiety is used for antibody linking via click chemistry.
  • “We are pleased to successfully be in line with the timeline of our Orano collaboration agreement to develop the first radio-immuno-conjugates therapy based on the Auger electron emitter.

Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy of Strengthening Development and Manufacturing Services for Life Science and Biopharma Customers

Retrieved on: 
Monday, July 17, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Quanta, Laboratory, Eye, Cancer, Doctor of Philosophy, Propylene glycol, Click chemistry, Plain City, Caliper Life Sciences, Acquisition, Drug discovery, Immunohistochemistry, Death, Pharmaceutical industry, Vector

This most recent acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.

Key Points: 
  • This most recent acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.
  • “This acquisition is valuable because it supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa V. Sellers , PhD, CEO of Vector Laboratories.
  • Quanta BioDesign was founded in 1997 by Paul D. Davis, PhD, in response to his wife’s death due to cancer.
  • Vector Laboratories was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence.

Acepodia Secures $100 Million Series D Financing to Advance

Retrieved on: 
Tuesday, June 6, 2023
ACC, Nobel Prize, Genetic engineering, Nobel Prize in Chemistry, Venture round, Cancer, CD20, Research, Click chemistry, Hematological Cancer Research Investment and Education Act, Patient, Non-Hodgkin lymphoma, Venture capital financing, Vaccine, Chemistry

ALAMEDA, Calif. and TAIPEI, June 6, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors. The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma. ACE 2016 is an anti-EGFR armed allogeneic gamma delta 2 T-cell therapy targeting EGFR-expressing solid tumors.

Key Points: 
  • ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma.
  • "This financing illustrates the confidence of Acepodia's current investors in our team, our mission, and our differentiated platform, and we are extremely grateful for their support," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia.
  • Acepodia has raised $259 million to date in venture capital financing, including a $109 million Series C round completed in December 2021.
  • Returning investors in the Series D included Digital Mobile Venture as the lead investor.